More from the company: RhoVac announces that the final patient in the clinical phase I/II study has had his/her blood sample taken

More from the company: RhoVac meddelar att det sista blodprovet i den kliniska fas I/II-studien är tagen för analys

Press release from Companies: RhoVac AB hires business development expert David Colpman as lead advisor to assist in identifying potentially interested parties in company's assets

Press release from Companies: RhoVac AB anlitar affärsutvecklaren David Colpman som ledande rådgivare för att identifiera potentiellt intresserade parter av bolagets tillgångar.

More from the company: RhoVac AB participates at BIO-Europe Spring in Amsterdam and at two Swedish investor meetings.

More from the company: RhoVac AB deltar vid BIO-Europe Spring i Amsterdam samt två svenska investerarevent.

Press release from Companies: RhoVac AB rapporterar positivt förmöte med den europeiska läkemedelsnämnden

Press release from Companies: RhoVac AB reports positive pre-submission meeting with the European Medicines Agency

Press release from Companies: RhoVac AB announces that all patients in company's clinical phase I/II study successfully completed their treatment phase with RV001.

Press release from Companies: RhoVac AB informerar att samtliga patienter i bolagets kliniska fas I/II-studie framgångsrikt avslutat sin behandlingsfas med RV001

Reports: RhoVac AB:s bokslutskommuniké för 2017 tillgänglig

More from the company: RhoVac AB förstärker projektkoordinering och kommunikation